纵向体重变化与MASLD临床结局的关联
该研究纳入16个三级中心的10,014例MASLD患者,评估纵向体重变化与肝脏相关事件(LREs)及肝硬度变化的关系。结果显示体重增加>5%与LREs风险升高及肝硬度进展相关,而体重下降>5%与肝硬度改善相关;肥胖逆转者的LREs风险与持续非肥胖者相当。
要点
- 体重增加>5%与LREs风险升高(aHR=1.84)及肝硬度进展(aOR=2.07)相关
- 体重下降>5%与肝硬度改善相关
- 肥胖逆转者的LREs风险与持续非肥胖者相当(aHR=1.44,P=0.435)
核心结论
- 在MASLD患者中,体重增加与LREs风险升高和肝硬度进展相关,而体重下降对肝硬度改善有益并在实现肥胖逆转者中改变LREs风险。
研究设计与样本
- 多中心队列研究,纳入16个三级中心的10,014例成人MASLD患者,至少2次体重测量。
- 体重变化分类:稳定(≤5%变化)、体重下降>5%、体重增加>5%;肥胖状态变化:持续非肥胖、持续肥胖、非肥胖转为肥胖、肥胖转为非肥胖。
- 采用多变量线性回归、Cox比例风险回归和逻辑回归,调整年龄、性别、 ethnicity、基线BMI、高血压、T2D、LSM、CAP及SGLT-2i/GLP-1RAs使用。
主要发现
- 体重测量间隔中位数29.2个月,末次体重评估后随访12.4个月期间发生123例LREs。
- 体重增加>5%与LREs风险升高相关(aHR=1.84,95%CI 1.01-3.09,P=0.020)。
- 体重增加>5%与肝硬度进展相关(aOR=2.07,95%CI 1.55-2.74,P<0.001)。
- 体重下降>5%与肝硬度改善相关。
- 进展为肥胖或持续肥胖者LREs风险更高,但肥胖逆转者LREs风险与持续非肥胖者相当(aHR=1.44,95%CI 0.57-3.61,P=0.435)。
临床怎么用
- 对MASLD患者应监测体重变化,体重增加>5%提示LREs和肝硬度进展风险升高。
- 体重下降>5%可能改善肝硬度,肥胖逆转可能降低LREs风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Weight control remains the cornerstone for metabolic dysfunction-associated steatotic liver disease (MASLD) management. We assessed the relationships between dynamic weight change and the risk of liver-related events (LREs) and liver stiffness changes in MASLD. APPROACH AND RESULTS: By enrolling adult MASLD individuals with ≥2 weight measurements from 16 tertiary referral centers, we assessed how longitude weight change, including the following categories (stable ≤5% change, weight loss >5% decrease, weight gain >5% increase) and changing status of obesity (persistent non-obesity, persistent obesity, transition from non-obesity to obesity, transition from obesity to non-obesity), were associated with LREs. Analyses were undertaken with multivariable linear regressions, Cox proportional hazards regression, and logistic regression, adjusting for age, sex, ethnicity, baseline BMI, hypertension, T2D, LSM, CAP, and SGLT-2i/GLP-1RAs usage. Analyses between weight change and liver stiffness change were also undertaken. A total of 10,014 MASLD individuals with ≥2 weight measurements were included. Over a measurement interval of 29.2 months, 123 LREs occurred during 12.4 months of follow-up after the final weight assessment. Weight gain >5% was associated with increased risk of LREs [aHR=1.84 (95% CI: 1.01-3.09), p =0.020] and liver stiffness progression [aOR=2.07 (95% CI: 1.55-2.74), p <0.001], while weight loss >5% exhibited liver stiffness improvement. Although those who progressed to or persisted with obesity had a higher LREs risk, obesity reversal had a comparable LREs risk [aHR=1.44 (95% CI: 0.57-3.61), p =0.435] to the persistent non-obese. CONCLUSIONS: In MASLD, weight gain is associated with increased LREs risks and liver stiffness progression. Conversely, weight loss confers benefits for liver stiffness improvement and modifies LREs risk in those who achieve obesity reversal.
引用
- Shi Y, Zhou R, Kim SU, et al. Association between longitudinal weight change and clinical outcome in individuals with MASLD. Hepatology. 2025. PMID: 41061041. doi:10.1097/HEP.0000000000001557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。